{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:40:01Z","timestamp":1792788001318,"version":"4.5.0"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the National Natural Science Foundation of China","award":["32301176"],"award-info":[{"award-number":["32301176"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Shandong Provincial Natural Science Foundation","award":["ZR2022QC133"],"award-info":[{"award-number":["ZR2022QC133"]}]},{"name":"Shandong Provincial Natural Science Foundation","award":["ZR2023MH280"],"award-info":[{"award-number":["ZR2023MH280"]}]},{"name":"Shandong Provincial Natural Science Foundation","award":["ZR2022MH100"],"award-info":[{"award-number":["ZR2022MH100"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04823-2","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:56:10Z","timestamp":1784609770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor microenvironment-responsive nanocarriers for enhanced glioblastoma immunotherapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Cuicui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"issue":"12 Suppl 2","key":"4823_CR1","first-page":"iv1","volume":"25","author":"QT Ostrom","year":"2016","unstructured":"Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016\u20132020. Neuro Oncol. 2016;25(12 Suppl 2):iv1-99.","journal-title":"Neuro Oncol"},{"issue":"1","key":"4823_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-024-00516-y","volume":"10","author":"M Weller","year":"2024","unstructured":"Weller M, Wen PY, Chang SM, et al. Glioma. Nat Rev Dis Primers. 2024;10(1):33.","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 5","key":"4823_CR3","first-page":"v1","volume":"24","author":"QT Ostrom","year":"2015","unstructured":"Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019. Neuro Oncol. 2015;24(Suppl 5):v1-95.","journal-title":"Neuro Oncol"},{"issue":"7","key":"4823_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41582-019-0220-2","volume":"15","author":"AM Molinaro","year":"2019","unstructured":"Molinaro AM, Taylor JW, Wiencke JK, et al. Genetic and molecular epidemiology of adult diffuse glioma. Nat Rev Neurol. 2019;15(7):405\u201317.","journal-title":"Nat Rev Neurol"},{"issue":"10412","key":"4823_CR5","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/S0140-6736(23)01054-1","volume":"402","author":"MJ Van Den Bent","year":"2023","unstructured":"Van Den Bent MJ, Geurts M, French PJ, et al. Primary brain tumours in adults. Lancet. 2023;402(10412):1564\u201379.","journal-title":"Lancet"},{"issue":"1","key":"4823_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41392-025-02299-4","volume":"10","author":"S Singh","year":"2025","unstructured":"Singh S, Dey D, Barik D, et al. Glioblastoma at the crossroads: current understanding and future therapeutic horizons. Signal Transduct Target Ther. 2025;10(1):213.","journal-title":"Signal Transduct Target Ther"},{"key":"4823_CR7","doi-asserted-by":"publisher","unstructured":"Kim YZ, Kim C-Y, Lim DH. The overview of practical guidelines for gliomas by KSNO, NCCN, and EANO. Brain Tumor Res Treat. 2022;10(2):83-93. https:\/\/doi.org\/10.14791\/btrt.2022.0001","DOI":"10.14791\/btrt.2022.0001"},{"issue":"3","key":"4823_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2020","unstructured":"Weller M, Van Den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2020;18(3):170\u201386.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"4823_CR9","first-page":"20230177","volume":"4","author":"F Bai","year":"2024","unstructured":"Bai F, Deng Y, Li L, et al. Advancements and challenges in brain cancer therapeutics[J]. Explor (Beijing). 2024;4(6):20230177.","journal-title":"Explor (Beijing)"},{"issue":"7","key":"4823_CR10","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jama.2023.0023","volume":"329","author":"LR Schaff","year":"2023","unstructured":"Schaff LR, Mellinghoff IK. Glioblastoma and Other Primary Brain Malignancies in Adults: A Review[J]. JAMA. 2023;329(7):574\u201387.","journal-title":"JAMA"},{"issue":"1","key":"4823_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-022-01260-z","volume":"8","author":"S Li","year":"2023","unstructured":"Li S, Wang C, Chen J, et al. Signaling pathways in brain tumors and therapeutic interventions[J]. Signal Transduct Target Therapy. 2023;8(1):8.","journal-title":"Signal Transduct Target Therapy"},{"issue":"5","key":"4823_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial[J]. Lancet Oncol. 2009;10(5):459\u201366.","journal-title":"Lancet Oncol"},{"issue":"4","key":"4823_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41578-021-00394-w","volume":"7","author":"E Nance","year":"2021","unstructured":"Nance E, Pun SH, Saigal R, et al. Drug delivery to the central nervous system. Nat Rev Mater. 2021;7(4):314\u201331.","journal-title":"Nat Rev Mater"},{"issue":"1","key":"4823_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","volume":"24","author":"M Zhang","year":"2025","unstructured":"Zhang M, Liu C, Tu J, et al. Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. Mol Cancer. 2025;24(1):136.","journal-title":"Mol Cancer"},{"issue":"3","key":"4823_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley RS, June CH, Langer R, et al. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18(3):175\u201396.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"4823_CR16","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon DA, Brandes AA, Omuro A, et al. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial[J]. JAMA Oncol. 2020;6(7):1003\u201310.","journal-title":"JAMA Oncol"},{"issue":"1","key":"4823_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"CD Arvanitis","year":"2020","unstructured":"Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20(1):26\u201341.","journal-title":"Nat Rev Cancer"},{"key":"4823_CR18","doi-asserted-by":"publisher","unstructured":"Song X, Qian H, Yu Y. Nanoparticles mediated the diagnosis and therapy of glioblastoma: bypass or cross the blood\u2013brain barrier. Small. 2023;19(45):2302613. https:\/\/doi.org\/10.1002\/smll.202302613","DOI":"10.1002\/smll.202302613"},{"key":"4823_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jconrel.2016.02.026","volume":"227","author":"R Karim","year":"2016","unstructured":"Karim R, Palazzo C, Evrard B, et al. Nanocarriers for the treatment of glioblastoma multiforme: current state-of-the-art. J Control Release. 2016;227:23\u201337.","journal-title":"J Control Release"},{"key":"4823_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1003651","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhao L, Zhang H, et al. The immunosuppressive microenvironment and immunotherapy in human glioblastoma. Front Immunol. 2022;13:1003651.","journal-title":"Front Immunol"},{"issue":"2","key":"4823_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.tips.2019.12.003","volume":"41","author":"H Wang","year":"2020","unstructured":"Wang H, Xu T, Huang Q, et al. Immunotherapy for Malignant Glioma: Current Status and Future Directions[J]. Trends Pharmacol Sci. 2020;41(2):123\u201338.","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"4823_CR22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","volume":"15","author":"M Lim","year":"2018","unstructured":"Lim M, Xia Y, Bettegowda C, et al. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018;15(7):422\u201342.","journal-title":"Nat Rev Clin Oncol"},{"key":"4823_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.addr.2019.06.007","volume":"143","author":"J Peng","year":"2019","unstructured":"Peng J, Yang Q, Shi K, et al. Intratumoral fate of functional nanoparticles in response to microenvironment factor: implications on cancer diagnosis and therapy. Adv Drug Deliv Rev. 2019;143:37\u201367.","journal-title":"Adv Drug Deliv Rev"},{"issue":"18","key":"4823_CR24","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","volume":"79","author":"DC Hinshaw","year":"2019","unstructured":"Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557\u201366.","journal-title":"Cancer Res"},{"issue":"1","key":"4823_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathmechdis-051122-110348","volume":"19","author":"MA Jayaram","year":"2024","unstructured":"Jayaram MA, Phillips JJ. Role of the microenvironment in glioma pathogenesis. Annu Rev Pathol Mech Dis. 2024;19(1):181\u2013201.","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"4823_CR26","doi-asserted-by":"publisher","unstructured":"Lu Q, Kou D, Lou S, et al. Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy. J Hematol Oncol. 2024;17:16. https:\/\/doi.org\/10.1186\/s13045-024-01535-8","DOI":"10.1186\/s13045-024-01535-8"},{"issue":"7","key":"4823_CR27","first-page":"1973","volume":"6","author":"M Yang","year":"2021","unstructured":"Yang M, Li J, Gu P, et al. The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment. Bioact Mater. 2021;6(7):1973\u201387.","journal-title":"Bioact Mater"},{"key":"4823_CR28","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jconrel.2022.09.065","volume":"352","author":"T Li","year":"2022","unstructured":"Li T, Li J, Chen Z, et al. Glioma diagnosis and therapy: Current challenges and nanomaterial-based solutions[J]. J Controlled Release. 2022;352:338\u201370.","journal-title":"J Controlled Release"},{"key":"4823_CR29","doi-asserted-by":"publisher","unstructured":"Wu T, Liu Y, Cao Y, et al. Engineering macrophage exosome disguised biodegradable nanoplatform for enhanced sonodynamic therapy of glioblastoma. Adv Mater. 2022;34(15):2110364.. https:\/\/doi.org\/10.1002\/adma.202110364","DOI":"10.1002\/adma.202110364"},{"key":"4823_CR30","doi-asserted-by":"publisher","unstructured":"Zhuo W, Wang W, Zhou W, et al. A targeted and responsive nanoprodrug delivery system for synergistic glioma chemotherapy. Small. 2024; 20(30):2400630. https:\/\/doi.org\/10.1002\/smll.202400630","DOI":"10.1002\/smll.202400630"},{"issue":"5","key":"4823_CR31","doi-asserted-by":"publisher","first-page":"6191","DOI":"10.1021\/acsnano.0c02249","volume":"14","author":"Z Yang","year":"2020","unstructured":"Yang Z, Du Y, Sun Q, et al. Albumin-based nanotheranostic probe with hypoxia alleviating potentiates synchronous multimodal imaging and phototherapy for glioma. ACS Nano. 2020;14(5):6191\u2013212.","journal-title":"ACS Nano"},{"key":"4823_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02776-y","author":"J Qi","year":"2024","unstructured":"Qi J, Zhang L, Ren Z, et al. Stepwise-targeting and hypoxia-responsive liposome AMVY@NPs carrying siYAP and verteporfin for glioblastoma therapy. J Nanobiotechnol. 2024;22:495. https:\/\/doi.org\/10.1186\/s12951-024-02776-y","journal-title":"J Nanobiotechnol"},{"issue":"12","key":"4823_CR33","doi-asserted-by":"publisher","first-page":"12269","DOI":"10.1021\/acsnano.8b06058","volume":"12","author":"W Tang","year":"2018","unstructured":"Tang W, Fan W, Wang Z, et al. Acidity\/Reducibility Dual-Responsive Hollow Mesoporous Organosilica Nanoplatforms for Tumor-Specific Self-Assembly and Synergistic Therapy[J]. ACS Nano. 2018;12(12):12269\u201383.","journal-title":"ACS Nano"},{"issue":"1","key":"4823_CR34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","volume":"20","author":"JH Sampson","year":"2019","unstructured":"Sampson JH, Gunn MD, Fecci PE, et al. Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer. 2019;20(1):12\u201325.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"4823_CR35","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41582-018-0025-8","volume":"14","author":"ML Broekman","year":"2018","unstructured":"Broekman ML, Maas SLN, Abels ER, et al. Multidimensional communication in the microenvirons of glioblastoma[J]. Nat Reviews Neurol. 2018;14(8):482\u201395.","journal-title":"Nat Reviews Neurol"},{"issue":"8","key":"4823_CR36","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","volume":"27","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Marabelle A, Eggermont A, et al. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482\u201392.","journal-title":"Ann Oncol"},{"issue":"5","key":"4823_CR37","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.immuni.2025.04.017","volume":"58","author":"KW Song","year":"2025","unstructured":"Song KW, Lim M, Monje M. Complex neural-immune interactions shape glioma immunotherapy. Immunity. 2025;58(5):1140\u201360.","journal-title":"Immunity"},{"key":"4823_CR38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.semcancer.2023.11.008","volume":"97","author":"R Abou Khouzam","year":"2023","unstructured":"Abou Khouzam R, Janji B, Thiery J, et al. Hypoxia as a potential inducer of immune tolerance, tumor plasticity and a driver of tumor mutational burden: impact on cancer immunotherapy. Semin Cancer Biol. 2023;97:104\u201323.","journal-title":"Semin Cancer Biol"},{"key":"4823_CR39","doi-asserted-by":"publisher","unstructured":"Chen Z, Han F, Du Y, et al. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8:70. https:\/\/doi.org\/10.1038\/s41392-023-01332-8","DOI":"10.1038\/s41392-023-01332-8"},{"issue":"3","key":"4823_CR40","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/0360-3016(94)90432-4","volume":"29","author":"R Rampling","year":"1994","unstructured":"Rampling R, Cruickshank G, Lewis AD, et al. Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys. 1994;29(3):427\u201331.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"4823_CR41","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0167-8140(99)00121-8","volume":"53","author":"DR Collingridge","year":"1999","unstructured":"Collingridge DR, Piepmeier JM, Rockwell S, et al. Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiother Oncol. 1999;53(2):127\u201331.","journal-title":"Radiother Oncol"},{"issue":"14","key":"4823_CR42","first-page":"3759","volume":"49","author":"F Kallinowski","year":"1989","unstructured":"Kallinowski F, Schlenger KH, Runkel S, et al. Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts[J]. Cancer Res. 1989;49(14):3759\u201364.","journal-title":"Cancer Res"},{"key":"4823_CR43","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.semcancer.2022.12.011","volume":"88","author":"C Liao","year":"2023","unstructured":"Liao C, Liu X, Zhang C, et al. Tumor hypoxia: from basic knowledge to therapeutic implications. Semin Cancer Biol. 2023;88:172\u201386.","journal-title":"Semin Cancer Biol"},{"issue":"10","key":"4823_CR44","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/s41416-020-1021-5","volume":"123","author":"DR Grimes","year":"2020","unstructured":"Grimes DR, Jansen M, Macauley RJ, et al. Evidence for hypoxia increasing the tempo of evolution in glioblastoma. Br J Cancer. 2020;123(10):1562\u20139.","journal-title":"Br J Cancer"},{"key":"4823_CR45","doi-asserted-by":"publisher","unstructured":"Wang F, Liu X, Li S, et al. Resolving the lineage relationship between malignant cells and vascular cells in glioblastomas. Protein Cell. 2022;14(2):105\u2013122. https:\/\/doi.org\/10.1093\/procel\/pwac006","DOI":"10.1093\/procel\/pwac006"},{"issue":"8","key":"4823_CR46","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrn2175","volume":"8","author":"RK Jain","year":"2007","unstructured":"Jain RK, Di Tomaso E, Duda DG, et al. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8(8):610\u201322.","journal-title":"Nat Rev Neurosci"},{"key":"4823_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202201888","author":"MT Ngo","year":"2022","unstructured":"Ngo MT, Sarkaria JN, Harley B. Perivascular stromal cells instruct glioblastoma invasion, proliferation, and therapeutic response within an engineered brain perivascular niche model. Adv Sci. 2022;9:2201888. https:\/\/doi.org\/10.1002\/advs.202201888","journal-title":"Adv Sci"},{"issue":"11","key":"4823_CR48","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.7150\/thno.81407","volume":"13","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zhang B, Lv C, et al. Single-cell RNA sequencing identifies critical transcription factors of tumor cell invasion induced by hypoxia microenvironment in glioblastoma. Theranostics. 2023;13(11):3744\u201360.","journal-title":"Theranostics"},{"issue":"17","key":"4823_CR49","doi-asserted-by":"publisher","first-page":"e2416231","DOI":"10.1002\/advs.202416231","volume":"12","author":"Q Wan","year":"2025","unstructured":"Wan Q, Wu X, Zhou J, et al. The Hypoxia-Associated High-Risk Cell Subpopulation Distinctly Enhances the Progression of Glioma[J]. Adv Sci (Weinh). 2025;12(17):e2416231.","journal-title":"Adv Sci (Weinh)"},{"key":"4823_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.914236","volume":"13","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Wang Z, Zhao M, et al. Single-cell transcriptomics revealed subtype-specific tumor immune microenvironments in human glioblastomas. Front Immunol. 2022;13:914236.","journal-title":"Front Immunol"},{"issue":"1","key":"4823_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01710-5","volume":"18","author":"Z Xu","year":"2025","unstructured":"Xu Z, Wang Y, Xie T, et al. Panoramic spatial enhanced resolution proteomics (PSERP) reveals tumor architecture and heterogeneity in gliomas. J Hematol Oncol. 2025;18(1):58.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"4823_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101238","volume":"4","author":"L Pang","year":"2023","unstructured":"Pang L, Guo S, Khan F, et al. Hypoxia-driven protease legumain promotes immunosuppression in glioblastoma. Cell Rep Med. 2023;4(11):101238.","journal-title":"Cell Rep Med"},{"issue":"8","key":"4823_CR53","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.immuni.2023.06.017","volume":"56","author":"A Sattiraju","year":"2023","unstructured":"Sattiraju A, Kang S, Giotti B, et al. Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression. Immunity. 2023;56(8):1825-e18436.","journal-title":"Immunity"},{"issue":"5","key":"4823_CR54","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.ccell.2024.03.013","volume":"42","author":"W Wang","year":"2024","unstructured":"Wang W, Li T, Cheng Y, et al. Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization. Cancer Cell. 2024;42(5):815-832.e12.","journal-title":"Cancer Cell"},{"issue":"3","key":"4823_CR55","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41590-020-00860-7","volume":"22","author":"JH Park","year":"2021","unstructured":"Park JH, Kim H-J, Kim CW, et al. Tumor hypoxia represses \u03b3\u03b4 T cell-mediated antitumor immunity against brain tumors. Nat Immunol. 2021;22(3):336\u201346.","journal-title":"Nat Immunol"},{"issue":"12","key":"4823_CR56","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1158\/2159-8290.CD-22-0196","volume":"12","author":"L Wu","year":"2022","unstructured":"Wu L, Wu W, Zhang J, et al. Natural coevolution of tumor and immunoenvironment in glioblastoma. Cancer Discov. 2022;12(12):2820\u201337.","journal-title":"Cancer Discov"},{"issue":"10","key":"4823_CR57","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.7150\/thno.93473","volume":"14","author":"Y Yang","year":"2024","unstructured":"Yang Y, Jin X, Xie Y, et al. The CEBPB+ glioblastoma subcluster specifically drives the formation of M2 tumor-associated macrophages to promote malignancy growth[J]. Theranostics. 2024;14(10):4107\u201326.","journal-title":"Theranostics"},{"issue":"6","key":"4823_CR58","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccr.2009.03.018","volume":"15","author":"Z Li","year":"2009","unstructured":"Li Z, Bao S, Wu Q, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 2009;15(6):501\u201313.","journal-title":"Cancer Cell"},{"issue":"19","key":"4823_CR59","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1016\/j.yexcr.2012.07.017","volume":"318","author":"L Yang","year":"2012","unstructured":"Yang L, Lin C, Wang L, et al. Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications. Exp Cell Res. 2012;318(19):2417\u201326.","journal-title":"Exp Cell Res"},{"issue":"10","key":"4823_CR60","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nrc1187","volume":"3","author":"GL Semenza","year":"2003","unstructured":"Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721\u201332.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"4823_CR61","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.molcel.2010.09.022","volume":"40","author":"AJ Majmundar","year":"2010","unstructured":"Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell. 2010;40(2):294\u2013309.","journal-title":"Mol Cell"},{"issue":"15","key":"4823_CR62","doi-asserted-by":"publisher","first-page":"5778","DOI":"10.7150\/thno.95141","volume":"14","author":"Z Chen","year":"2024","unstructured":"Chen Z, Wang J, Peng P, et al. Hypoxia-induced TGFBI maintains glioma stem cells by stabilizing EphA2. Theranostics. 2024;14(15):5778\u201392.","journal-title":"Theranostics"},{"key":"4823_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216801","volume":"590","author":"M Dong","year":"2024","unstructured":"Dong M, Zhang X, Peng P, et al. Hypoxia-induced TREM1 promotes mesenchymal-like states of glioma stem cells via alternatively activating tumor-associated macrophages. Cancer Lett. 2024;590:216801.","journal-title":"Cancer Lett"},{"key":"4823_CR64","doi-asserted-by":"publisher","unstructured":"Ding Y, Zhan Q, Cui L, et al. VITA-GBM: EPIC-0502-driven HIF1\u03b1 degradation overcomes bevacizumab resistance and synergizes with TMZ in glioblastoma. Neuro Oncol. 2025;28(4):864\u2013879. https:\/\/doi.org\/10.1093\/neuonc\/noaf293","DOI":"10.1093\/neuonc\/noaf293"},{"issue":"9","key":"4823_CR65","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3109\/00207454.2013.789874","volume":"123","author":"J Reszec","year":"2013","unstructured":"Reszec J, Rutkowski R, Chyczewski L. The expression of hypoxia-inducible factor-1 in primary brain tumors. Int J Neurosci. 2013;123(9):657\u201362.","journal-title":"Int J Neurosci"},{"key":"4823_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.637454","volume":"9","author":"J Zhang","year":"2021","unstructured":"Zhang J, Zhang Y, Mo F, et al. The roles of HIF-1\u03b1 in radiosensitivity and radiation-induced bystander effects under hypoxia. Front Cell Dev Biol. 2021;9:637454.","journal-title":"Front Cell Dev Biol"},{"key":"4823_CR67","doi-asserted-by":"publisher","unstructured":"Sun T, Liu B, Li Y, et al. Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation. J Exp Clin Cancer Res. 2023;42:253. https:\/\/doi.org\/10.1186\/s13046-023-02815-w","DOI":"10.1186\/s13046-023-02815-w"},{"issue":"1","key":"4823_CR68","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10555-021-09997-9","volume":"41","author":"L Barthel","year":"2021","unstructured":"Barthel L, Hadamitzky M, Dammann P, et al. Glioma: molecular signature and crossroads with tumor microenvironment[J]. Cancer Metastasis Rev. 2021;41(1):53\u201375.","journal-title":"Cancer Metastasis Rev"},{"issue":"19","key":"4823_CR69","doi-asserted-by":"publisher","first-page":"5845","DOI":"10.1158\/0008-5472.CAN-15-2630","volume":"76","author":"A Filatova","year":"2016","unstructured":"Filatova A, Seidel S, B\u00f6\u011f\u00fcrc\u00fc N, et al. Acidosis acts through HSP90 in a PHD\/VHL-independent manner to promote HIF function and stem cell maintenance in glioma. Cancer Res. 2016;76(19):5845\u201356.","journal-title":"Cancer Res"},{"issue":"5","key":"4823_CR70","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.immuni.2024.04.006","volume":"57","author":"A De Leo","year":"2024","unstructured":"De Leo A, Ugolini A, Yu X, et al. Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma[J]. Immunity. 2024;57(5):1105\u2013e11238.","journal-title":"Immunity"},{"issue":"8","key":"4823_CR71","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1093\/neuonc\/noae040","volume":"26","author":"S Yang","year":"2024","unstructured":"Yang S, Zhan Q, Su D, et al. HIF1\u03b1\/ATF3 partake in PGK1 K191\/K192 succinylation by modulating P4HA1\/succinate signaling in glioblastoma. Neuro Oncol. 2024;26(8):1405\u201320.","journal-title":"Neuro Oncol"},{"issue":"1","key":"4823_CR72","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41392-024-01763-x","volume":"9","author":"Y Yan","year":"2024","unstructured":"Yan Y, Zhou S, Chen X, et al. Suppression of ITPKB degradation by Trim25 confers TMZ resistance in glioblastoma through ROS homeostasis. Signal Transduct Target Ther. 2024;9(1):58.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4823_CR73","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1038\/s41467-021-24108-6","volume":"12","author":"H Huang","year":"2021","unstructured":"Huang H, Zhang S, Li Y, et al. Suppression of mitochondrial ROS by prohibitin drives glioblastoma progression and therapeutic resistance[J]. Nat Commun. 2021;12(1):3720.","journal-title":"Nat Commun"},{"key":"4823_CR74","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0065-230X(10)07003-X","volume":"107","author":"D Mougiakakos","year":"2010","unstructured":"Mougiakakos D, Choudhury A, Lladser A, et al. Regulatory T cells in cancer[J]. Adv Cancer Res. 2010;107:57\u2013117.","journal-title":"Adv Cancer Res"},{"issue":"10","key":"4823_CR75","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"Pyonteck SM, Akkari L, Schuhmacher AJ, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264\u201372.","journal-title":"Nat Med"},{"key":"4823_CR76","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009175","author":"MM Elguindy","year":"2024","unstructured":"Elguindy MM, Young JS, Ho WS, et al. Co-evolution of glioma and immune microenvironment. J Immunother Cancer. 2024:12:e009175. https:\/\/doi.org\/10.1136\/jitc-2024-009175","journal-title":"J Immunother Cancer"},{"issue":"23","key":"4823_CR77","doi-asserted-by":"publisher","first-page":"5876","DOI":"10.1158\/0008-5472.CAN-21-1456","volume":"81","author":"F Dong","year":"2021","unstructured":"Dong F, Qin X, Wang B, et al. ALKBH5 facilitates hypoxia-induced paraspeckle assembly and IL8 secretion to generate an immunosuppressive tumor microenvironment. Cancer Res. 2021;81(23):5876\u201388.","journal-title":"Cancer Res"},{"key":"4823_CR78","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.canlet.2019.03.040","volume":"452","author":"D Wang","year":"2019","unstructured":"Wang D, Yang L, Yue D, et al. Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion. Cancer Lett. 2019;452:244\u201353.","journal-title":"Cancer Lett"},{"key":"4823_CR79","doi-asserted-by":"publisher","unstructured":"Korbecki J, Kojder K, Simi\u0144ska D, et al. CC chemokines in a tumor: a review of pro-cancer and anti-cancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4. Int J Mol Sci. 2020;21(21):8412. https:\/\/doi.org\/10.3390\/ijms21218412","DOI":"10.3390\/ijms21218412"},{"key":"4823_CR80","doi-asserted-by":"publisher","first-page":"114115","DOI":"10.1016\/j.addr.2022.114115","volume":"182","author":"S Quader","year":"2022","unstructured":"Quader S, Kataoka K, Cabral H. Nanomedicine for brain cancer[J]. Adv Drug Deliv Rev. 2022;182:114115.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"4823_CR81","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/neuonc\/nox175","volume":"20","author":"JN Sarkaria","year":"2018","unstructured":"Sarkaria JN, Hu LS, Parney IF, et al. Is the blood\u2013brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro-oncol. 2018;20(2):184\u201391.","journal-title":"Neuro-oncol"},{"issue":"3","key":"4823_CR82","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1021\/acsnano.3c10674","volume":"18","author":"S Zha","year":"2024","unstructured":"Zha S, Liu H, Li H, et al. Functionalized nanomaterials capable of crossing the blood\u2013brain barrier. ACS Nano. 2024;18(3):1820\u201345.","journal-title":"ACS Nano"},{"key":"4823_CR83","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202402445","volume":"36","author":"J Liao","year":"2024","unstructured":"Liao J, Gong L, Xu Q, et al. Revolutionizing neurocare: biomimetic nanodelivery via cell membranes. Adv Mater. 2024;36:e2402445.","journal-title":"Adv Mater"},{"issue":"1","key":"4823_CR84","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s12951-024-02776-y","volume":"22","author":"J Qi","year":"2024","unstructured":"Qi J, Zhang L, Ren Z, et al. Stepwise-targeting and hypoxia-responsive liposome AMVY@NPs carrying siYAP and verteporfin for glioblastoma therapy[J]. J Nanobiotechnol. 2024;22(1):495.","journal-title":"J Nanobiotechnol"},{"issue":"29","key":"4823_CR85","doi-asserted-by":"publisher","first-page":"16044","DOI":"10.1002\/anie.202103557","volume":"60","author":"P Su","year":"2021","unstructured":"Su P, Pei W, Wang X, et al. Exceptional electrochemical HER performance with enhanced electron transfer between Ru nanoparticles and single atoms dispersed on a carbon substrate. Angew Chem Int Ed Engl. 2021;60(29):16044\u201350.","journal-title":"Angew Chem Int Ed Engl"},{"key":"4823_CR86","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jconrel.2019.12.041","volume":"319","author":"R Kumari","year":"2020","unstructured":"Kumari R, Sunil D, Ningthoujam RS. Hypoxia-responsive nanoparticle based drug delivery systems in cancer therapy: An up-to-date review[J]. J Control Release. 2020;319:135\u201356.","journal-title":"J Control Release"},{"issue":"47","key":"4823_CR87","doi-asserted-by":"publisher","first-page":"52319","DOI":"10.1021\/acsami.0c12971","volume":"12","author":"H Xu","year":"2020","unstructured":"Xu H, Han Y, Zhao G, et al. Hypoxia-Responsive Lipid-Polymer Nanoparticle-Combined Imaging-Guided Surgery and Multitherapy Strategies for Glioma[J]. ACS Appl Mater Interfaces. 2020;12(47):52319\u201328.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"4823_CR88","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/med.20137","volume":"29","author":"Y Chen","year":"2009","unstructured":"Chen Y, Hu L. Design of anticancer prodrugs for reductive activation[J]. Med Res Rev. 2009;29(1):29\u201364.","journal-title":"Med Res Rev"},{"key":"4823_CR89","doi-asserted-by":"publisher","first-page":"6551","DOI":"10.2147\/IJN.S173431","volume":"13","author":"Y Zeng","year":"2018","unstructured":"Zeng Y, Ma J, Zhan Y, et al. Hypoxia-activated prodrugs and redox-responsive nanocarriers[J]. Int J Nanomed. 2018;13:6551\u201374.","journal-title":"Int J Nanomed"},{"issue":"18","key":"4823_CR90","doi-asserted-by":"publisher","first-page":"5088","DOI":"10.7150\/thno.26225","volume":"8","author":"L Hua","year":"2018","unstructured":"Hua L, Wang Z, Zhao L, et al. Hypoxia-responsive lipid-poly-(hypoxic radiosensitized polyprodrug) nanoparticles for glioma chemo- and radiotherapy. Theranostics. 2018;8(18):5088\u2013105.","journal-title":"Theranostics"},{"key":"4823_CR91","doi-asserted-by":"publisher","first-page":"102614","DOI":"10.1016\/j.mtbio.2025.102614","volume":"35","author":"J Wang","year":"2025","unstructured":"Wang J, Zhang Z, Li A, et al. Hydroxylated dendrimer nanogels co-deliver drugs and cytokines for chemoimmunotherapy of glioma[J]. Mater Today Bio. 2025;35:102614.","journal-title":"Mater Today Bio"},{"issue":"4","key":"4823_CR92","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41571-025-01000-6","volume":"22","author":"SW Linderman","year":"2025","unstructured":"Linderman SW, Deridder L, Sanjurjo L, et al. Enhancing immunotherapy with tumour-responsive nanomaterials. Nat Rev Clin Oncol. 2025;22(4):262\u201382.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"4823_CR93","doi-asserted-by":"publisher","first-page":"e1701156","DOI":"10.1002\/adhm.201701156","volume":"7","author":"L Wang","year":"2018","unstructured":"Wang L, Huo M, Chen Y, et al. Tumor Microenvironment-Enabled Nanotherapy[J]. Adv Healthc Mater. 2018;7(8):e1701156.","journal-title":"Adv Healthc Mater"},{"issue":"3","key":"4823_CR94","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1039\/D4MH01356E","volume":"12","author":"A Zhu","year":"2025","unstructured":"Zhu A, Shao S, Hu J, et al. Hydrogen sulfide-generating semiconducting polymer nanoparticles for amplified radiodynamic-ferroptosis therapy of orthotopic glioblastoma. Mater Horiz. 2025;12(3):973\u201386.","journal-title":"Mater Horiz"},{"issue":"18","key":"4823_CR95","doi-asserted-by":"publisher","first-page":"17247","DOI":"10.1021\/acsnano.4c11892","volume":"19","author":"M Li","year":"2025","unstructured":"Li M, Zhan Y, Li Z, et al. X-ray-responsive semiconducting polymer siRNA nanosystems for orthotopic glioma treatment via silencing the immunosuppressive signal. ACS Nano. 2025;19(18):17247\u201360.","journal-title":"ACS Nano"},{"key":"4823_CR96","doi-asserted-by":"publisher","first-page":"102545","DOI":"10.1016\/j.redox.2022.102545","volume":"58","author":"C Taze","year":"2022","unstructured":"Taze C, Drakouli S, Samiotaki M, et al. Short-term hypoxia triggers ROS and SAFB mediated nuclear matrix and mRNA splicing remodeling[J]. Redox Biol. 2022;58:102545.","journal-title":"Redox Biol"},{"issue":"null","key":"4823_CR97","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.2147\/IJN.S140462","volume":"13","author":"K Graham","year":"2018","unstructured":"Graham K, Unger E. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment[J]. Int J Nanomed. 2018;13(null):6049\u201358.","journal-title":"Int J Nanomed"},{"key":"4823_CR98","doi-asserted-by":"publisher","unstructured":"Barba I, Carrillo-Bosch L, Seoane J. Targeting the Warburg effect in cancer: where do we stand? Int J Mol Sci. 2024;25(6):3142. https:\/\/doi.org\/10.3390\/ijms25063142","DOI":"10.3390\/ijms25063142"},{"issue":"3","key":"4823_CR99","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.apsb.2023.12.003","volume":"14","author":"M Liao","year":"2024","unstructured":"Liao M, Yao D, Wu L, et al. Targeting the Warburg effect: a revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer. Acta Pharm Sin B. 2024;14(3):953\u20131008.","journal-title":"Acta Pharm Sin B"},{"issue":"47","key":"4823_CR100","doi-asserted-by":"publisher","first-page":"52354","DOI":"10.1021\/acsami.0c14288","volume":"12","author":"J Liu","year":"2020","unstructured":"Liu J, Zhang Y, Chen T, et al. Environmentally self-adaptative nanocarriers suppress glioma proliferation and stemness via codelivery of shCD163 and doxorubicin. ACS Appl Mater Interfaces. 2020;12(47):52354\u201369.","journal-title":"ACS Appl Mater Interfaces"},{"key":"4823_CR101","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.msec.2018.12.139","volume":"98","author":"A Pandey","year":"2019","unstructured":"Pandey A, Singh K, Patel S, et al. Hyaluronic acid tethered pH-responsive alloy-drug nanoconjugates for multimodal therapy of glioblastoma: an intranasal route approach. Mater Sci Eng C Mater Biol Appl. 2019;98:419\u201336.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"4823_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106338","volume":"180","author":"J Du","year":"2023","unstructured":"Du J, Sun J, Liu X, et al. Preparation of C6 cell membrane-coated doxorubicin conjugated manganese dioxide nanoparticles and its targeted therapy application in glioma. Eur J Pharm Sci. 2023;180:106338.","journal-title":"Eur J Pharm Sci"},{"key":"4823_CR103","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.msec.2017.03.201","volume":"76","author":"X Feng","year":"2017","unstructured":"Feng X, Li D, Han J, et al. Schiff base bond-linked polysaccharide-doxorubicin conjugate for upregulated cancer therapy. Mater Sci Eng C Mater Biol Appl. 2017;76:1121\u20138.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"4823_CR104","doi-asserted-by":"publisher","unstructured":"Fang X, Chen Z, Zhou W, et al. Boosting glioblastoma therapy with targeted pyroptosis induction. Small. 2023;19:2207604. https:\/\/doi.org\/10.1002\/smll.202207604","DOI":"10.1002\/smll.202207604"},{"key":"4823_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101878","volume":"32","author":"J Zhao","year":"2025","unstructured":"Zhao J, Niu X, Luo L, et al. A pH-responsive PEG coating strategy for enhancing the enrichment of small extracellular vesicles towards disease regions with acidic microenvironment. Mater Today Bio. 2025;32:101878.","journal-title":"Mater Today Bio"},{"issue":"1","key":"4823_CR106","doi-asserted-by":"publisher","first-page":"7672","DOI":"10.1038\/s41467-025-63081-2","volume":"16","author":"R Zhao","year":"2025","unstructured":"Zhao R, Hou Y, Li B, et al. Bioengineered hybrid dual-targeting nanoparticles reprogram the tumour microenvironment for deep glioblastoma photodynamic therapy[J]. Nat Commun. 2025;16(1):7672.","journal-title":"Nat Commun"},{"key":"4823_CR107","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.biomaterials.2014.10.007","volume":"37","author":"S Ruan","year":"2015","unstructured":"Ruan S, Yuan M, Zhang L, et al. Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles. Biomaterials. 2015;37:425\u201335.","journal-title":"Biomaterials"},{"issue":"6","key":"4823_CR108","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202503530","volume":"15","author":"K Deng","year":"2026","unstructured":"Deng K, Gao W, Wen Y, et al. A functional nanocomposite tri-activates cuproptosis, ferroptosis, and mitophagy death pathway to oppose malignancies. Adv Healthc Mater. 2026;15(6):e03530.","journal-title":"Adv Healthc Mater"},{"key":"4823_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122708","volume":"311","author":"J Li","year":"2024","unstructured":"Li J, Yang J, Jiang S, et al. Targeted reprogramming of tumor-associated macrophages for overcoming glioblastoma resistance to chemotherapy and immunotherapy. Biomaterials. 2024;311:122708.","journal-title":"Biomaterials"},{"issue":"1","key":"4823_CR110","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1021\/am800042v","volume":"1","author":"M Liu","year":"2009","unstructured":"Liu M, Yue X, Dai Z, et al. Novel thrombo-resistant coating based on iron-polysaccharide complex multilayers. ACS Appl Mater Interfaces. 2009;1(1):113\u201323.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"38","key":"4823_CR111","doi-asserted-by":"publisher","first-page":"34742","DOI":"10.1021\/jacs.5c10422","volume":"147","author":"K Zheng","year":"2025","unstructured":"Zheng K, Ouyang X, Li J, et al. Zwitterionic sulfadiazine-based micelle achieves effective drug delivery to glioblastoma by overcoming multiple biological barriers. J Am Chem Soc. 2025;147(38):34742\u201357.","journal-title":"J Am Chem Soc"},{"issue":"24","key":"4823_CR112","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202411689","volume":"21","author":"W Lin","year":"2025","unstructured":"Lin W, Wei R, Lai S, et al. Acid-responsive disassembly of nanomedicines for extracellular drug delivery reversing glioblastoma immunosuppressive microenvironment by targeting the adenosine-A2AR pathway. Small. 2025;21(24):e2411689.","journal-title":"Small"},{"issue":"25","key":"4823_CR113","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202500882","volume":"12","author":"S Zhang","year":"2025","unstructured":"Zhang S, Shang K, Gong L, et al. Smart organic-inorganic copolymer nanoparticles distinguish between microglia and cancer cells for synergistic immunotherapy in glioma. Adv Sci. 2025;12(25):e2500882.","journal-title":"Adv Sci"},{"key":"4823_CR114","doi-asserted-by":"publisher","unstructured":"He C, Zhang Z, Ding Y, et al. LRP1-mediated pH-sensitive polymersomes facilitate combination therapy of glioblastoma in vitro and in vivo. J Nanobiotechnol. 2021;19:29. https:\/\/doi.org\/10.1186\/s12951-020-00751-x","DOI":"10.1186\/s12951-020-00751-x"},{"key":"4823_CR115","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jconrel.2019.08.010","volume":"310","author":"M Zhou","year":"2019","unstructured":"Zhou M, Jiang N, Fan J, et al. H7K(R2)2-modified pH-sensitive self-assembled nanoparticles delivering small interfering RNA targeting hepatoma-derived growth factor for malignant glioma treatment. J Control Release. 2019;310:24\u201335.","journal-title":"J Control Release"},{"issue":"41","key":"4823_CR116","doi-asserted-by":"publisher","first-page":"10665","DOI":"10.1039\/D4TB01262C","volume":"12","author":"N Aggarwal","year":"2024","unstructured":"Aggarwal N, Singh G, Panda HS, et al. Unravelling the potential of l-carnosine analog-based nano-assemblies as pH-responsive therapeutics in treating glioma: an in vitro perspective. J Mater Chem B. 2024;12(41):10665\u201381.","journal-title":"J Mater Chem B"},{"key":"4823_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123216","volume":"319","author":"R Wei","year":"2025","unstructured":"Wei R, Xie K, Li T, et al. Immunity\/metabolism dual-regulation via an acidity-triggered bioorthogonal assembly nanoplatform enhances glioblastoma immunotherapy by targeting CXCL12\/CXCR4 and adenosine-A2AR pathways. Biomaterials. 2025;319:123216.","journal-title":"Biomaterials"},{"issue":"1","key":"4823_CR118","doi-asserted-by":"publisher","first-page":"10418","DOI":"10.1038\/s41467-024-54382-z","volume":"15","author":"B Li","year":"2024","unstructured":"Li B, Chen G, Zhong H, et al. \u03b3-Glutamyl transpeptidase-activable nanoprobe crosses the blood-brain barrier for immuno-sonodynamic therapy of glioma[J]. Nat Commun. 2024;15(1):10418.","journal-title":"Nat Commun"},{"issue":"8","key":"4823_CR119","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.7150\/thno.125403","volume":"16","author":"YH Tseng","year":"2026","unstructured":"Tseng YH, Lin JY, Chuang CP, et al. Engineering a modular FAP-targeting ferritin-based drug nanocarrier for enhanced glioblastoma theranostics. Theranostics. 2026;16(8):4169\u201389.","journal-title":"Theranostics"},{"key":"4823_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125931","volume":"682","author":"S Tapponi","year":"2025","unstructured":"Tapponi S, Yusuf A, Alsaafin F, et al. Breaking barriers with pH-responsive nanocarriers: a new frontier in precision oncology. Int J Pharm. 2025;682:125931.","journal-title":"Int J Pharm"},{"issue":"1","key":"4823_CR121","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12951-021-01221-8","volume":"20","author":"P Zhang","year":"2022","unstructured":"Zhang P, Chen D, Li L, et al. Charge reversal nano-systems for tumor therapy. J Nanobiotechnol. 2022;20(1):31.","journal-title":"J Nanobiotechnol"},{"issue":"23","key":"4823_CR122","doi-asserted-by":"publisher","first-page":"23223","DOI":"10.1021\/acsnano.3c06019","volume":"17","author":"D Wei","year":"2023","unstructured":"Wei D, Sun Y, Zhu H, et al. Stimuli-responsive polymer-based nanosystems for cancer theranostics. ACS Nano. 2023;17(23):23223\u201361.","journal-title":"ACS Nano"},{"issue":"4","key":"4823_CR123","doi-asserted-by":"publisher","first-page":"342","DOI":"10.2174\/1570159X16666180302120925","volume":"17","author":"MJ Ram\u00edrez-Exp\u00f3sito","year":"2019","unstructured":"Ram\u00edrez-Exp\u00f3sito MJ, Mart\u00ednez-Martos JM. The delicate equilibrium between oxidants and antioxidants in brain glioma. Curr Neuropharmacol. 2019;17(4):342\u201351.","journal-title":"Curr Neuropharmacol"},{"issue":"23","key":"4823_CR124","doi-asserted-by":"publisher","first-page":"11590","DOI":"10.1039\/D4CS00404C","volume":"53","author":"X Jia","year":"2024","unstructured":"Jia X, Wang Y, Qiao Y, et al. Nanomaterial-based regulation of redox metabolism for enhancing cancer therapy. Chem Soc Rev. 2024;53(23):11590\u2013656.","journal-title":"Chem Soc Rev"},{"issue":"12","key":"4823_CR125","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","volume":"12","author":"C Gorrini","year":"2013","unstructured":"Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12(12):931\u201347.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"4823_CR126","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/10408360500523878","volume":"43","author":"JM Estrela","year":"2006","unstructured":"Estrela JM, Ortega A, Obrador E. Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci. 2006;43(2):143\u201381.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"4823_CR127","doi-asserted-by":"publisher","unstructured":"Lee J, Kang Y, Lee H, et al. Amplifying glioblastoma immunotherapy: T cell shielding through nitric oxide\/reactive oxygen species scavenging nanoparticles potentiates anti-PD-1. Biomaterials. 2025;315:122904. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122904","DOI":"10.1016\/j.biomaterials.2024.122904"},{"issue":"1","key":"4823_CR128","doi-asserted-by":"publisher","first-page":"1600124","DOI":"10.1002\/advs.201600124","volume":"4","author":"G Saravanakumar","year":"2017","unstructured":"Saravanakumar G, Kim J, Kim WJ. Reactive-Oxygen-Species-Responsive Drug Delivery Systems: Promises and Challenges[J]. Adv Sci (Weinh). 2017;4(1):1600124.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"4823_CR129","doi-asserted-by":"publisher","first-page":"e2103836","DOI":"10.1002\/advs.202103836","volume":"9","author":"S Peng","year":"2022","unstructured":"Peng S, Xiao F, Chen M, et al. Tumor-Microenvironment-Responsive Nanomedicine for Enhanced Cancer Immunotherapy[J]. Adv Sci (Weinh). 2022;9(1):e2103836.","journal-title":"Adv Sci (Weinh)"},{"key":"4823_CR130","doi-asserted-by":"publisher","unstructured":"Geraldo LH, Xu Y, Jacob L, et al. SLIT2\/ROBO signaling in tumor-associated microglia and macrophages drives glioblastoma immunosuppression and vascular dysmorphia. J Clin Invest. 2021;131(16):e141083. https:\/\/doi.org\/10.1172\/JCI141083","DOI":"10.1172\/JCI141083"},{"key":"4823_CR131","doi-asserted-by":"publisher","unstructured":"Chen A, Jiang Y, Li Z, et al. Chitinase-3-like 1 protein complexes modulate macrophage-mediated immune suppression in glioblastoma. J Clin Invest. 2021;131(16):e147552. https:\/\/doi.org\/10.1172\/JCI147552","DOI":"10.1172\/JCI147552"},{"issue":"15","key":"4823_CR132","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202418053","volume":"37","author":"H You","year":"2025","unstructured":"You H, Zhang S, Zhang Y, et al. Engineered bacterial outer membrane vesicles-based doxorubicin and CD47-siRNA co-delivery nanoplatform overcomes immune resistance to potentiate the immunotherapy of glioblastoma. Adv Mater. 2025;37(15):e2418053.","journal-title":"Adv Mater"},{"issue":"12","key":"4823_CR133","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/s41565-024-01769-0","volume":"19","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Qin J, Yu D, et al. Polymer-locking fusogenic liposomes for glioblastoma-targeted siRNA delivery and CRISPR\u2013Cas gene editing. Nat Nanotechnol. 2024;19(12):1869\u201379.","journal-title":"Nat Nanotechnol"},{"key":"4823_CR134","doi-asserted-by":"publisher","unstructured":"Zhang H, Jiang W, Song T, et al. Lipid-polymer nanoparticles mediate compartmentalized delivery of Cas9 and sgRNA for glioblastoma vasculature and immune reprogramming. Adv Sci. 2024;11(32):2309314. https:\/\/doi.org\/10.1002\/advs.202309314","DOI":"10.1002\/advs.202309314"},{"issue":"37","key":"4823_CR135","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201903277","volume":"31","author":"M Zheng","year":"2019","unstructured":"Zheng M, Liu Y, Wang Y, et al. ROS-Responsive polymeric siRNA nanomedicine stabilized by triple interactions for the robust glioblastoma combinational RNAi therapy. Adv Mater. 2019;31(37):e1903277.","journal-title":"Adv Mater"},{"issue":"7","key":"4823_CR136","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202512104","volume":"38","author":"X Kang","year":"2026","unstructured":"Kang X, Chen W, Zhang Y, et al. A sono-responsive nanoplatform integrating STING activation and CXCR4 blockade for synergistic immunotherapy of glioblastoma. Adv Mater. 2026;38(7):e12104.","journal-title":"Adv Mater"},{"issue":"12","key":"4823_CR137","doi-asserted-by":"publisher","first-page":"20607","DOI":"10.1021\/acsnano.2c07491","volume":"16","author":"R An","year":"2022","unstructured":"An R, Liu L, Wei S, et al. Controlling disassembly of paramagnetic prodrug and photosensitizer nanoassemblies for on-demand orthotopic glioma theranostics. ACS Nano. 2022;16(12):20607\u201321.","journal-title":"ACS Nano"},{"key":"4823_CR138","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jconrel.2021.06.015","volume":"336","author":"S Qiao","year":"2021","unstructured":"Qiao S, Cheng Y, Liu M, et al. Chemoattractants driven and microglia based biomimetic nanoparticle treating TMZ-resistant glioblastoma multiforme. J Control Release. 2021;336:54\u201370.","journal-title":"J Control Release"},{"issue":"8","key":"4823_CR139","doi-asserted-by":"publisher","first-page":"8129","DOI":"10.1021\/acsnano.8b02980","volume":"12","author":"Y Liu","year":"2018","unstructured":"Liu Y, Yang Z, Huang X, et al. Glutathione-responsive self-assembled magnetic gold nanowreath for enhanced tumor imaging and imaging-guided photothermal therapy. ACS Nano. 2018;12(8):8129\u201337.","journal-title":"ACS Nano"},{"issue":"30","key":"4823_CR140","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202400630","volume":"20","author":"W Zhuo","year":"2024","unstructured":"Zhuo W, Wang W, Zhou W, et al. A targeted and responsive nanoprodrug delivery system for synergistic glioma chemotherapy. Small. 2024;20(30):e2400630.","journal-title":"Small"},{"issue":"12","key":"4823_CR141","doi-asserted-by":"publisher","first-page":"20377","DOI":"10.1021\/acsnano.1c08689","volume":"15","author":"T Xiao","year":"2021","unstructured":"Xiao T, He M, Xu F, et al. Macrophage membrane-camouflaged responsive polymer nanogels enable magnetic resonance imaging-guided chemotherapy\/chemodynamic therapy of orthotopic glioma. ACS Nano. 2021;15(12):20377\u201390.","journal-title":"ACS Nano"},{"issue":"1","key":"4823_CR142","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/s41467-024-44963-3","volume":"15","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Xu X, Du J, et al. Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy[J]. Nat Commun. 2024;15(1):1118.","journal-title":"Nat Commun"},{"issue":"21","key":"4823_CR143","doi-asserted-by":"publisher","first-page":"27187","DOI":"10.1021\/acsami.4c05831","volume":"16","author":"T Huang","year":"2024","unstructured":"Huang T, Guo Y, Wang Z, et al. Biomimetic dual-target theranostic nanovaccine enables magnetic resonance imaging and chemo\/chemodynamic\/immune therapy of glioma. ACS Appl Mater Interfaces. 2024;16(21):27187\u2013201.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"8","key":"4823_CR144","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202516608","volume":"38","author":"J Zhou","year":"2026","unstructured":"Zhou J, Tian Z, Chen Y, et al. Shutting down the \u2018language encoder\u2019: a pathogen-derived nano-interferer disrupt sialylation metabolism and reprogram intercellular communication in glioblastoma. Adv Mater. 2026;38(8):e16608.","journal-title":"Adv Mater"},{"issue":"1","key":"4823_CR145","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12951-025-03182-8","volume":"23","author":"C Zou","year":"2025","unstructured":"Zou C, Liu X, Wang W, et al. Targeting GDF15 to enhance immunotherapy efficacy in glioblastoma through tumor microenvironment-responsive CRISPR-Cas9 nanoparticles[J]. J Nanobiotechnol. 2025;23(1):126.","journal-title":"J Nanobiotechnol"},{"issue":"22","key":"4823_CR146","doi-asserted-by":"publisher","first-page":"14469","DOI":"10.1021\/acsnano.4c01253","volume":"18","author":"Q Fan","year":"2024","unstructured":"Fan Q, Kuang L, Wang B, et al. Multiple synergistic effects of the microglia membrane-bionic nanoplatform on mediate tumor microenvironment remodeling to amplify glioblastoma immunotherapy. ACS Nano. 2024;18(22):14469\u201386.","journal-title":"ACS Nano"},{"key":"4823_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2026.126814","volume":"696","author":"MR Keivany","year":"2026","unstructured":"Keivany MR, Asrami ES. Engineering stimuli-responsive prodrugs to overcome barriers in cancer immunotherapy. Int J Pharm. 2026;696:126814.","journal-title":"Int J Pharm"},{"issue":"20","key":"4823_CR148","doi-asserted-by":"publisher","first-page":"e2300153","DOI":"10.1002\/adhm.202300153","volume":"12","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Ding C, Sun T, et al. Tumor Therapy Strategies Based on Microenvironment-Specific Responsive Nanomaterials[J]. Adv Healthc Mater. 2023;12(20):e2300153.","journal-title":"Adv Healthc Mater"},{"issue":"4","key":"4823_CR149","volume":"2","author":"P Zhang","year":"2021","unstructured":"Zhang P, Meng J, Li Y, et al. Nanotechnology-enhanced immunotherapy for metastatic cancer. Innovation (Camb). 2021;2(4):100174.","journal-title":"Innovation (Camb)"},{"issue":"3","key":"4823_CR150","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1021\/acsami.4c15671","volume":"17","author":"Q Li","year":"2025","unstructured":"Li Q, Zhang Z, Wu X, et al. Cascade-responsive nanoparticles for efficient CRISPR\/Cas9-based glioblastoma gene therapy. ACS Appl Mater Interfaces. 2025;17(3):4480\u20139.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"8","key":"4823_CR151","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202202063","volume":"12","author":"R Cheng","year":"2023","unstructured":"Cheng R, Santos HA. Smart nanoparticle-based platforms for regulating tumor microenvironment and cancer immunotherapy. Adv Healthc Mater. 2023;12(8):e2202063.","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"4823_CR152","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1039\/C7TB02160G","volume":"6","author":"P Wang","year":"2018","unstructured":"Wang P, Yu N, Wang Y, et al. Co-delivery of PLK1-specific shRNA and doxorubicin via core-crosslinked pH-sensitive and redox ultra-sensitive micelles for glioma therapy. J Mater Chem B. 2018;6(1):112\u201324.","journal-title":"J Mater Chem B"},{"key":"4823_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123730","volume":"327","author":"Z Zheng","year":"2026","unstructured":"Zheng Z, Chen J, Kang Y, et al. Dual-responsive nanoparticle system for enhanced blood-brain barrier crossing and glioblastoma penetration. Biomaterials. 2026;327:123730.","journal-title":"Biomaterials"},{"issue":"29","key":"4823_CR154","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202504253","volume":"37","author":"Q Xu","year":"2025","unstructured":"Xu Q, Hu X, Ullah I, et al. Biomimetic hybrid PROTAC nanovesicles block multiple DNA repair pathways to overcome temozolomide resistance against orthotopic glioblastoma. Adv Mater. 2025;37(29):e2504253.","journal-title":"Adv Mater"},{"issue":"3","key":"4823_CR155","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adr8841","volume":"11","author":"Z Li","year":"2025","unstructured":"Li Z, Jiang S, Wang J, et al. Peptide-drug conjugates repolarize glioblastoma-associated macrophages to resensitize chemo-immunotherapy of glioblastoma. Sci Adv. 2025;11(3):eadr8841.","journal-title":"Sci Adv"},{"issue":"22","key":"4823_CR156","doi-asserted-by":"publisher","first-page":"14145","DOI":"10.1021\/acsnano.3c03409","volume":"18","author":"P Dosta","year":"2024","unstructured":"Dosta P, Dion MZ, Prado M, et al. Matrix metalloproteinase- and pH-sensitive nanoparticle system enhances drug retention and penetration in glioblastoma. ACS Nano. 2024;18(22):14145\u201360.","journal-title":"ACS Nano"},{"key":"4823_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123634","volume":"325","author":"L Chen","year":"2026","unstructured":"Chen L, Huang J, Liu L, et al. Multimodal cascade-amplified phototheranostics for enhanced anti-tumor immunity. Biomaterials. 2026;325:123634.","journal-title":"Biomaterials"},{"key":"4823_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.ntm.2025.100092","volume":"4","author":"J Wu","year":"2025","unstructured":"Wu J, Xue X, Qu H. Tumor microenvironment-responsive nanoplatforms for enhanced cancer immunotherapy: advances and synergistic strategies. Nano TransMed. 2025;4:100092.","journal-title":"Nano TransMed"},{"issue":"1","key":"4823_CR159","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1186\/s12951-022-01731-z","volume":"20","author":"P Zhao","year":"2022","unstructured":"Zhao P, Tian Y, Lu Y, et al. Biomimetic calcium carbonate nanoparticles delivered IL-12 mRNA for targeted glioblastoma sono-immunotherapy by ultrasound-induced necroptosis[J]. J Nanobiotechnol. 2022;20(1):525.","journal-title":"J Nanobiotechnol"},{"key":"4823_CR160","doi-asserted-by":"publisher","unstructured":"Sun P, Wu Z, Xiao Y, et al. TfR-T12 short peptide and pH sensitive cell transmembrane peptide modified nano-composite micelles for glioma treatment via remodeling tumor microenvironment. Nanomedicine (Lond). 2022;41:102516. https:\/\/doi.org\/10.1016\/j.nano.2022.102516","DOI":"10.1016\/j.nano.2022.102516"},{"key":"4823_CR161","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.jconrel.2024.04.043","volume":"370","author":"T Shan","year":"2024","unstructured":"Shan T, Wang W, Fan M, et al. Effective glioblastoma immune sonodynamic treatment mediated by macrophage cell membrane cloaked biomimetic nanomedicines. J Control Release. 2024;370:866\u201378.","journal-title":"J Control Release"},{"issue":"18","key":"4823_CR162","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201705054","volume":"30","author":"C Qiao","year":"2018","unstructured":"Qiao C, Yang J, Shen Q, et al. Traceable nanoparticles with dual targeting and ROS response for RNAi-based immunochemotherapy of intracranial glioblastoma treatment. Adv Mater. 2018;30(18):1705054.","journal-title":"Adv Mater"},{"issue":"32","key":"4823_CR163","doi-asserted-by":"publisher","first-page":"e2309314","DOI":"10.1002\/advs.202309314","volume":"11","author":"H Zhang","year":"2024","unstructured":"Zhang H, Jiang W, Song T, et al. Lipid-Polymer Nanoparticles Mediate Compartmentalized Delivery of Cas9 and sgRNA for Glioblastoma Vasculature and Immune Reprogramming[J]. Adv Sci (Weinh). 2024;11(32):e2309314.","journal-title":"Adv Sci (Weinh)"},{"key":"4823_CR164","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202516608","author":"J Zhou","year":"2025","unstructured":"Zhou J, Tian Z, Chen Y, et al. Shutting down the \u2018language encoder\u2019: a pathogen-derived nano\u2010interferer disrupt sialylation metabolism and reprogram intercellular communication in glioblastoma. Adv Mater. 2025;38(8):e16608. https:\/\/doi.org\/10.1002\/adma.202516608","journal-title":"Adv Mater"},{"key":"4823_CR165","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-026-04055-4","author":"Y Li","year":"2026","unstructured":"Li Y, Bao K, Huan R, et al. RAP-peptide functionalized biomimetic nanoformulation with pathological ROS\/pH-responsive drug release for target immunotherapy in glioma. J Nanobiotechnol. 2026;24:225. https:\/\/doi.org\/10.1186\/s12951-026-04055-4","journal-title":"J Nanobiotechnol"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04823-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04823-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04823-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:02:16Z","timestamp":1792162936000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04823-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":165,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4823"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04823-2","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"17 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors give their consent for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"962"}}